[HTML][HTML] Advances in immunotherapy for triple-negative breast cancer
Y Liu, Y Hu, J Xue, J Li, J Yi, J Bu, Z Zhang, P Qiu… - Molecular cancer, 2023 - Springer
Background Immunotherapy has recently emerged as a treatment strategy which stimulates
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
the human immune system to kill tumor cells. Tumor immunotherapy is based on immune …
[HTML][HTML] Triple-negative breast cancer: a review of current curative intent therapies
I MacDonald, NA Nixon, OF Khan - Current Oncology, 2022 - mdpi.com
Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative
breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options …
breast cancer (TNBC) accounting for 10–20% of cases. Historically, fewer treatment options …
[HTML][HTML] Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients
The complexity of breast cancer includes many interacting biological processes that make it
difficult to find appropriate therapeutic treatments. Therefore, identifying potential diagnostic …
difficult to find appropriate therapeutic treatments. Therefore, identifying potential diagnostic …
[HTML][HTML] KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer
L Yao, Q Hao, M Wang, Y Chen, H Cao, Q Zhang, K Yu… - Oncogene, 2023 - nature.com
Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype and
accounts for approximately 15–20% of breast cancer cases. In this study, we identified …
accounts for approximately 15–20% of breast cancer cases. In this study, we identified …
A Carrier-Free Nanomedicine Enables Apoptosis-Ferroptosis Synergistic Breast Cancer Therapy by Targeting Subcellular Organelles
J Zhu, K Zhang, Y Zhou, R Wang, L Gong… - … Applied Materials & …, 2023 - ACS Publications
The heterogeneity of cancer cells disables the single-cell death patterns in subtypes of cells
with different genotypes and phenotypes, such as refractory triple-negative breast cancer …
with different genotypes and phenotypes, such as refractory triple-negative breast cancer …
Design, synthesis, and biological evaluation of novel 4, 4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple …
G Gao, J Li, Y Cao, X Li, Y Qian, X Wang, M Li… - European Journal of …, 2023 - Elsevier
Abstract Cyclin-dependent kinase 9 (CDK9) is directly related to tumor development in triple-
negative breast cancer (TNBC) patients. Increased CDK9 is significantly associated with …
negative breast cancer (TNBC) patients. Increased CDK9 is significantly associated with …
[HTML][HTML] The tumor suppressor BRCA1/2, cancer susceptibility and genome instability in gynecological and mammary cancers
Y Oubaddou, FB Ali, FE Oubaqui… - Asian Pacific Journal …, 2023 - ncbi.nlm.nih.gov
BRCA1 and BRCA2 germline alterations highly predispose women to breast and ovarian
cancers. They are mostly found within the TNBC (Triple-Negative Breast Cancer) and the …
cancers. They are mostly found within the TNBC (Triple-Negative Breast Cancer) and the …
[HTML][HTML] Ceramide synthase 6 mediates triple-negative breast cancer response to chemotherapy through RhoA-and EGFR-mediated signaling pathways
H Chen, B He, F Ke - Journal of Breast Cancer, 2022 - ncbi.nlm.nih.gov
Purpose Limited treatment options and lack of treatment sensitivity biomarkers make the
clinical management of triple-negative breast cancer (TNBC) challenging. Ceramide …
clinical management of triple-negative breast cancer (TNBC) challenging. Ceramide …
Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition
W Yang, C Zhou, Q Sun, G Guan - Canadian Journal of …, 2022 - cdnsciencepub.com
Aberrant upregulation of mitochondrial biogenesis is observed in breast cancer and holds
potential therapeutic option. In our work, we showed that inhibition of mitochondrial function …
potential therapeutic option. In our work, we showed that inhibition of mitochondrial function …
[HTML][HTML] Rationale and clinical research progress on PD-1/PD-L1-based immunotherapy for metastatic triple-negative breast cancer
Y Ren, J Song, X Li, N Luo - International Journal of Molecular Sciences, 2022 - mdpi.com
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor,
currently lacks an effective treatment. There has been some progress in the treatment of …
currently lacks an effective treatment. There has been some progress in the treatment of …